Pfizer Inc. or Perrigo Company plc: Who Leads in Yearly Revenue?

Pfizer vs. Perrigo: A Decade of Revenue Dynamics

In the ever-evolving pharmaceutical landscape, Pfizer Inc. and Perrigo Company plc have showcased distinct revenue trajectories over the past decade. From 2014 to 2023, Pfizer consistently outperformed Perrigo, with its revenue peaking at a staggering $100 billion in 2022, marking a 100% increase from its 2014 figures. In contrast, Perrigo's revenue remained relatively stable, fluctuating around the $4 billion to $5 billion range, with a modest 15% growth over the same period.

The year 2021 was particularly notable for Pfizer, as its revenue surged by 94% compared to the previous year, likely driven by its COVID-19 vaccine success. Meanwhile, Perrigo's revenue saw a slight dip in 2021, highlighting the contrasting fortunes of these two giants. This decade-long analysis underscores Pfizer's dominant market position and its ability to capitalize on global health trends.